Main Article Content
Objective: It is necessary to provide PSA alternatives or methods that can be used in conjunction with PSA to regress complications rising from negative biopsies and to increase diagnostic value.
Patients and Methods: The study is consisting of 59 men as the sample group. Blood samples from the individuals are grouped as prostate cancer and BPH (benign prostatic hyperplasia) groups. 27 prostate cancer patients whom some of them also operated are assembled in the patients group and the other 32 individuals are grouped as BPH group. Micro RNA expression levels evaluated by RT-PCR.
Results: Prostate cancer group when compared with the control group, it is observed that expression levels of miRNA-221 and miRNA-432 increased while expression levels of miRNA-17-5p, miRNA-30c, miRNA-107, miRNA-141, miRNA-145, miRNA-181a-2, miRNA-331-3p, miRNA-574-3p decreased and expression levels of miRNA-21 and miRNA-375 are quite similar between the groups.
Conclusion: The prospect of strong and sensitive serum miRNA expression levels in prostate cancer cases which are easily detectable by non-invasive methods as biomarkers is a promising field of study. Nevertheless, it is currently necessary to work in conjunction with both tissue and serum to enhance both sensitivity and specificity of miRNAs as biomarkers. As such, expression levels of the same miRNAs in tissue and serum provide different expression values which in turn make it difficult to indicate a common biomarker.
Siegel R, Naishadham D, Jemal A. Cancer Statistics. Cancer Journal For Clinicians. 2012;62(1):10-29.
Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369:603.
Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet. 2006;15:R17-R29.
Kent OA, Mendell JT. A small piece in the cancer puzzle: MicroRNAs as tumor suppressors and oncogenes. Oncogene. 2006;25(46):6188-6196.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834-838.
Wach S, Nolte E, Szczyrba J, Stöhr R, Hartmann A, Orntoft T et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. International Journal of Cancer. 2012;130(3):611-621.
Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E. A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group. J. Clin. Med. 2015;4:1369-1379.
Kitapcı A, Dastan T, Dündar G, Pektas AN, Durna Daştan S, Korgalı E, Türkoglu Ş. Methylation of the E-cadherin (ECAD) gene in clear cell renal cell carcinoma (CCRCC). Fresenius Environmental Bulletin. 2020;29:85-91.
Konaç E, Önen Hİ, Sözen S. Üroonkolojide mikro RNA (miRNA) Yeri ve önemi. Üroonkoloji Bülteni. 2010;1.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 20081,141:672-675.
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166-1176.
Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469-77.
Zhang ZW, An Y, Teng CB. The roles of miR-17-92 cluster in mammal development and tumorigenesis. YiChuan. 2009;31(11):1094-1100.
Beatriz AW, Vladimir AV, Peter AP, Maria JM. Comprehensive microRNA Profiling of Prostate Cancer. J Cancer. 2013;4(5):350-357.
Parikh A, Lee C, Joseph P. MicroRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nature Communications. 2014;5:2977.
Wei Z, Cui L, Mei Z, Liu M, Zhang D. miR-181a mediates metabolic shift in colon cancer cells via the PTEN/AKT pathway. FEBS Letters. 2014;588(9):1773-1779.
Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play. Prostate Cancer. 2013;539680.
Simonini SR, Breiling A, Gupta N. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor α in breast cancer cells. Cancer Res. 201;70:9175-9184.
Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miRNA-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009;284(37):24696-704.
Sun R, Fu X, Li Y, Xie Y, Mao Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics. 2009;10:93.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009;69(18):7165-7169.
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther. 2009;16:206-216.
Agaoglu YF, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N. Investigation of miRNA-21, miRNA-141, and miRNA-221 in blood circulation of patients with prostate cancer. TumourBiol. 2011;32:583-588.
Hellwinkel OJ, Sellier C, Slyvester YM, Brase JC, Isbarn H, Erbersdobler A, et al. A Cancer-Indicative microRNA Pattern in Normal Prostate Tissue. Int J Mol Sci. 2013;14(3):5239-5249. doi: 10.3390/ijms14035239.
Huang X, Liang M, Dittmar R, Wang L. Extracellular MicroRNAs in Urologic Malignancies: Chances and Challenges. Int J Mol Sci. 2013;14(7):14785-14799.
Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front. Genet. 2013;4. doi: 10.3389/fgene.2013.00036.
Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoSOne. 2009;4:e6229.
Chiyomaru T, Yamamura S, Fukuhara S, Hidaka H, Majid S, Saini S, et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. R. PLoSOne. 2013;8(3):e58929. doi: 10.1371/journal.pone.0058929.